Fighting cancer with light-activated drug delivery by nanoparticle

Date: Mar-03-2014A new type of treatment called "light-activated drug delivery" is showing promise as a

way to give doctors control over precisely where and when drugs are delivered inside the

patient's body. Now, researchers have developed a light-activated way to target cancer cells

without hurting healthy tissue by using drug-carrying nanoparticles.

Jeffrey Zink, professor of chemistry and biochemistry, and Fuyu Tamanoi, professor of

microbiology, immunology and molecular genetics, both at University of California Los Angeles in the US, and colleagues, report their findings in the journal SMALL.

Their method uses nanoparticles - particles that are so small their size is compatible with

cell dimensions - to carry chemotherapy drugs directly to tumor cells and release them when

activated by a two-photon laser in the infrared red wavelength.

Not only can the nanoparticles ferry drugs to precisely targeted

areas of the body, but they are fluorescent and their progress can be tracked.

This ability to track a targeted therapy is an example of a new blend of therapy and diagnostics, dubbed "theranostics."

Being able to precisely pinpoint the target in the body so the chemotherapy drug only hits

tumor cells and not neighboring healthy tissue, greatly reduces the side effects of treatment

and increase a drug's cancer-killing power.

The new nanoparticles can absorb energy from tissue-penetrating light

This study is important because developing a drug delivery system that is triggered by light

that can penetrate tissue has proved very challenging.

For their study the researchers developed a new type of nanoparticle that can absorb energy

from tissue-penetrating light.

The nanoparticles are made of silica and have thousands of tiny pores in which they carry the

chemotherapy drugs. To stop the drugs leaking out, the ends of the pores are capped with

nanovalves, like corks in bottles.

It is the nanovalves that respond to the light trigger. They contain special molecules that

react when exposed to two-photon light, causing the valves to open and release their drug cargo.

Two-photon light is a laser technique that excites electrons into different states, which in

turn can change the properties of any compounds they form part of.

The researchers successfully tested their nanoscale drug-carrier and its trigger on lab-cultured human breast cancer cells. Because the light trigger only works up to a range of 4 cm of tissue, the technique

is limited to tumors that are not far from the skin surface, such as breast, colon, ovarian and

stomach tumors.

The nanoparticles are fluorescent, so their progress in the body can be followed using

molecular imaging techniques and researchers can see exactly where the nanoparticle is before

activating drug release.

The research team also included members from French research centers, including Jean-Olivier

Durand from the University of Montpellier, who was instrumental in developing the new

nanoparticle.

Funds from the National Institutes of Health and the French American Cultural Exchange -

Partner University Fund (FACE-PUF) helped finance the study.

In April 2012, Medical News Today reported on research into nano factories that could produce drugs at tumor sites. The nano-factories in that study could be activated by UV light to produce protein-based drugs right next to tumors. Cancer-figthing protein-based drugs exist, but they are limited by the fact the body breaks them down before they can reach their target.

Written by Catharine Paddock PhD




View all articles written by Catharine, or follow Catharine on:




Copyright: Medical News Today

Not to be reproduced without the permission of Medical News Today.

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.